Millipore Sigma Vibrant Logo

Draw on Our Experience in Gene Therapy

The VirusExpress™ Lentiviral Production Platform

A transfection-based solution to lentivirus production challenges using a suspension cell line, chemically defined medium, and a process with proven performance at scale. With a platform that can dramatically reduce the time in process development and scale-up in your facilities or by leveraging our CDMO capabilities you can draw on our experience to speed your gene therapy to patients.

The VirusExpress™ Lentiviral Production Platform offers

    VirusExpress™ 293T Lentiviral Production Cells

  • Cells banked and characterized in conformance with FDA cGMP regulations (21 CFR 210, 211, 600, 610)
  • Suspension Adapted Cells
  • Optimized Cells for Transient Transfection

    EX-CELL® CD HEK293 Viral Vector Medium

  • Chemically defined medium
  • GMP-manufactured (coming soon!)
  • 1 L bottle or 10 L bag catalog SKUs available

    Proven Process

  • Upstream production and downstream purification processes developed at 50 L scale
  • Commercial license available for clinical use

Featured Product Highlight

The VirusExpress™ Lentiviral Production Platform provides a scalable and high-yield lentiviral vector production platform. Transient transfection of a suspension-adapted HEK 293T derived production cells in chemically defined medium (Figure 1) shows proven performance at clinically relevant scale while utilizing a simplified process. Optimal viral titers have been demonstrated in 3 production runs at a 40 L working volume (Figure 2). The VirusExpress Lentiviral Production Platform features not only cells and chemically defined medium but also proven process performance to help you speed your gene therapy to patients.

Cell Growth and Viability
Cell viability and cell growth data

Figure 1. Cell viability (dashed lined) and cell growth data (solid lines)


Titer values of three unique bioreactor production runs
Each run exceeded a target functional titer of 1 x 107 TU/mL and demonstrated successful scale-up to 40 L

Figure 2. Each run exceeded a target functional titer of 1 x 107 TU/mL
and demonstrated successful scale-up to 40 L

Download the VirusExpress™ Lentiviral Production Platform White Paper

Process Development and scale-up for Transient Transfection-Based Lentivirus Production in suspension White Paper.

Download White Paper

Ordering Information

To place an order, please click on the button below:

Place an Order

For more Information

For information regarding the cell line, medium, and licenses available, please click on the button below:

Learn More

Related Resources

The VirusExpress platform offers a transfection-based solution using a suspension cell line, chemically defined medium, and a process with proven performance at scale. Draw on our 30+ years of viral vector manufacturing experience and a platform that can dramatically reduce your process development and scale-up time to speed your therapy to patients. Find out how we can help bring your gene therapy to life.

Request More Information